Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.62 | -0.32 | -0.44 | 1.74 |
| FCF Yield | -2.84% | -3.30% | -2.87% | -1.40% |
| EV / EBITDA | -27.09 | -23.49 | -27.87 | -47.52 |
| Quality | ||||
| ROIC | -12.64% | -10.52% | -8.50% | -6.86% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.74 | 0.91 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -31.24% | -33.96% | -43.81% | -39.69% |
| Free Cash Flow Growth | -25.30% | 0.71% | -36.51% | -3.71% |
| Safety | ||||
| Net Debt / EBITDA | 0.43 | 0.03 | 0.40 | 2.27 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 1,823.43 | -429.32 |